Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9, which plays a key role in transcription regulation. This compound shows promise in oncology for disrupting the expression of pro-survival genes in cancer cells, especially in hematological malignancies. It is investigated for its ability to induce apoptosis in tumor cells by blocking RNA polymerase II phosphorylation. Its structure allows for high binding affinity to the ATP-binding site of CDK9, making it a valuable scaffold in developing targeted cancer therapies. Also employed as a chemical probe to study transcriptional control in cellular models.